Update on nephrogenic systemic fibrosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent
Udgivelsesdato: 2008/11
Udgivelsesdato: 2008/11
Originalsprog | Engelsk |
---|---|
Tidsskrift | Magnetic Resonance Imaging Clinics of North America |
Vol/bind | 16 |
Udgave nummer | 4 |
Sider (fra-til) | 551-60, vii |
ISSN | 1064-9689 |
Status | Udgivet - 2008 |
ID: 13911450